0.89
-6.26%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Exicure
From its filings with the US Securities and Exchange Commission
Exicure is based in Chicago, Illinois and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker XCUR. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $4.9m. At that date it held total assets of $14.0m and shareholders' equity of $3.9m.
Historically, we have been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, we announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that we were exploring strategic alternatives to maximize stockholder value. In February 2024, we received an upfront payment of $500,000 from a licensing agreement for patents related to one of our historical drug candidates, and received a small, one-time payment and an entitlement to only modest royalties on future sales of the licensed technology that we do not believe will be material. In the second quarter of 2024, we recognized other income of $637,000 from the sale of our samples related to the licensed product. In the third quarter of 2024, we sold our historical biotechnology intellectual property and other assets (including the licensing agreement described above) pursuant to the purchase agreement and recognized other income of $1,500,000. We continue to engage in a broader exploration of strategic alternatives. This effort involves exploring growth through transactions with potential partners that see opportunity in joining an existing, publicly-traded organization.
Quoted from its 10-K, filed 25 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 9 May 2018
- Employees
- 8
- Website
- exicuretx.com ↗
- Head office
- 2430 N. HALSTED ST., CHICAGO, IL, 60614
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Josephine CardarelliPresident, Chief Scientific Officer
- Mr. Andy YooChief Executive Officer, Director, since 2024$27,167
- Mr. Seung Ik BaikChief Financial Officer, Secretary, Director, since 2024$5,778
- Ms. Aejin HwangIndependent Director
- Mr. Dongho LeeIndependent Director$20,000
- Mr. Sangjn YeoIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 43
- Environment
- 43
- Social
- 66
- Governance
- 19
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Exicure's SNA technology unlocks therapeutic oligonucleotides in diverse cells and tissues.
- AST-008 targets immuno-oncology with TLR9 agonist for anti-cancer immune response.
- XCUR-FXN addresses Friedreich’s ataxia in preclinical development for genetic disorders.
Weaknesses
- Exicure has only 8 employees in a clinical-stage biotechnology sector.
- The company's IPO in 2018 has limited financial resources for R&D expansion.
- Limited pipeline with only three products in development stages.
Opportunities
- Expanding SNA technology applications in immuno-oncology and genetic disorders.
- XCUR17 targets IL-17RA for inflammatory disorders and hair loss treatments.
- Collaborations with pharmaceutical companies for SNA technology commercialization.
Threats
- Competition from established biotech firms in immuno-oncology sector.
- Regulatory hurdles for clinical-stage biotechnology companies in the US.
- High costs of developing therapies for rare genetic disorders like Friedreich’s ataxia.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.